Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 7,301 Shares

Key Points

• Insider sale: Director Jason Adair sold 7,301 shares on April 13 at an average price of $38.37 for $280,139, using a pre-arranged Rule 10b5-1 plan to cover tax withholding and reducing his stake by 3.28% to 215,426 shares (≈$8.27M).
• Stock snapshot: LQDA recently traded around $38.71 with a market cap of $3.41B, a 12‑month range of $11.85–$46.67, 50/200‑day SMAs of $36.87/$32.92, and a negative P/E of -46.64.
• Fundamentals and analyst view: Liquidia beat Q results (EPS $0.15 vs. $0.08) and reported $92.02M revenue (up ~3,072% YoY), while analysts hold a "Moderate Buy" consensus with an average price target of $43.44 and several firms raising targets into the $50–$55 range.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 7,301 shares of the company's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $38.37, for a total value of $280,139.37. Following the transaction, the insider directly owned 215,426 shares in the company, valued at approximately $8,265,895.62. The trade was a 3.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, January 26th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $41.65, for a total value of $28,655.20.

Liquidia Stock Performance

NASDAQ LQDA traded down $0.14 during trading hours on Tuesday, hitting $38.71. The company's stock had a trading volume of 844,813 shares, compared to its average volume of 1,775,539. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $46.67. The company's 50 day simple moving average is $36.87 and its two-hundred day simple moving average is $32.92. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The company has a market cap of $3.41 billion, a P/E ratio of -46.64 and a beta of 0.45.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. The business's revenue was up 3072.4% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several large investors have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia in the fourth quarter worth approximately $25,000. Covestor Ltd lifted its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after buying an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter valued at $30,000. FNY Investment Advisers LLC bought a new position in Liquidia in the 3rd quarter worth $34,000. Finally, NewEdge Advisors LLC bought a new position in shares of Liquidia in the second quarter worth about $25,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Needham & Company LLC lifted their target price on shares of Liquidia from $52.00 to $54.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. HC Wainwright increased their price target on Liquidia from $50.00 to $55.00 and gave the company a "buy" rating in a report on Friday, March 6th. Jefferies Financial Group raised their price target on Liquidia from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, January 13th. BTIG Research lifted their price objective on Liquidia from $49.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Finally, Lifesci Capital upgraded Liquidia to a "strong-buy" rating in a research report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and a consensus price target of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.